RT Journal Article
SR Electronic
T1 Prevalence and Burden of Chronic Hepatitis B Virus Infection in Sierra Leone, 1997-2022: Evidence from a 25-Year Systematic Review and Meta-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.16.22282393
DO 10.1101/2022.11.16.22282393
A1 Yendewa, George A.
A1 Wang, Gi-Ming
A1 James, Peter B.
A1 Massaquoi, Samuel P.E.
A1 Yendewa, Sahr A.
A1 Ghazawi, Manal
A1 Babawo, Lawrence S.
A1 Ocama, Ponsiano
A1 Russell, James B.W.
A1 Deen, Gibrilla F.
A1 Sahr, Foday
A1 Kabba, Mustapha
A1 Tatsuoka, Curtis
A1 Lakoh, Sulaiman
A1 Salata, Robert A.
YR 2022
UL http://medrxiv.org/content/early/2022/11/17/2022.11.16.22282393.abstract
AB Objective To estimate the prevalence and burden of chronic HBV in Sierra Leone.Methods We used electronic databases PubMed/MEDLINE, Embase, Scopus, ScienceDirect, Web of Science, Google Scholar and African Journals Online to systematically review articles reporting hepatitis B surface antigen (HBsAg) seroprevalence estimates in Serra Leone during 1997-2022. We estimated pooled HBV seroprevalence rates and assessed sources of heterogeneityResults Of 406 publications screened, 22 studies of total sample size 107,186 were included in the meta-analysis. The crude pooled HBV seroprevalence was 13.0% (95% CI 10.0-16.0) (I2=99%, p-heterogeneity<0.01), translating into 1.06 million people (95% uncertainty interval 0.81-1.30) or 1 in 8 Sierra Leoneans living with chronic HBV in 2021. Sensitivity analysis yielded a pooled HBV seroprevalence of 12.0% (95% CI 10.0-14.0) (sample size 104,968) (I2=98%, p-heterogeneity<0.001). The highest HBV seroprevalence estimates were among adolescents aged 10-17 years (17.0%, 95% CI 8.8-30.5), Ebola survivors (36.8%, 95% CI 26.2-48.8), people living with HIV (15.9%, 95% CI 10.6-23.0) and in the Northern (19.0%, 95% CI 6.4-44.7) and Southern (19.7%, 95% CI 10.9-32.8) regions. HBV seroprevalence progressively declined from 17.9% during 1997-2014 to 10.7% during 2020-2022.Conclusions These findings necessitate the urgent implementation of national HBV prevention and control programs in Sierra Leone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by grants to GAY from the National Institutes of Health (NIH)/AIDS Clinical Trials Group (ACTG) under Award Numbers 5UM1AI068636-15 and 5UM1AI069501-09, the Roe Green Center for Travel Medicine and Global Health/University Hospitals Cleveland Medical Center Award Number J0713 and the University Hospitals Minority Faculty Career Development Award/University Hospitals Cleveland Medical Center Award Number P0603. The funders had no role in the review process.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study used data from published articles that are freely available in the public domain and therefore did not require ethical approval.